Cargando…

Efficacy and safety of Lianhua Qingwen combined with conventional antiviral Western Medicine in the treatment of coronavirus disease (covid-19) in 2019: Protocol for a systematic review and meta-analysis

BACKGROUND: The novel coronavirus pneumonia (COVID-19) has spread to >200 countries and regions. There is no effective antiviral drug for COVID-19. Traditional Chinese medicine, such as Lianhua Qingwen, has achieved some curative effect in many countries, but its effect is not clear. We aim to as...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiaolin, Cao, Di, Liu, Junnan, Zhang, Qi, Liu, Mingjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387000/
https://www.ncbi.nlm.nih.gov/pubmed/32791754
http://dx.doi.org/10.1097/MD.0000000000021404
_version_ 1783564053574057984
author Zhang, Xiaolin
Cao, Di
Liu, Junnan
Zhang, Qi
Liu, Mingjun
author_facet Zhang, Xiaolin
Cao, Di
Liu, Junnan
Zhang, Qi
Liu, Mingjun
author_sort Zhang, Xiaolin
collection PubMed
description BACKGROUND: The novel coronavirus pneumonia (COVID-19) has spread to >200 countries and regions. There is no effective antiviral drug for COVID-19. Traditional Chinese medicine, such as Lianhua Qingwen, has achieved some curative effect in many countries, but its effect is not clear. We aim to assess the efficacy and safety of Lianhua Qingwen combined with Conventional antiviral Western Medicine in Clinical treatment of COVID-19 or asymptomatic infection. METHODS: The following electronic bibliographic databases will be searched to identify relevant studies: CNKI, CBM, VIP and Wanfang databases, PubMed, EMBASE, MEDLINE, Cochrane central, and clinical trial registration centers, such as China Clinical Trial Registration Center (ChiCTR), Netherlands National Trial Registration Center (NTR) and clinical trials.gov. In addition, Manual retrieval of articles, conference papers, ongoing experiments, internal reports, among others, to supplement electronic retrieval. Select all eligible studies published before May 8, 2020. According to the Cochrane Handbook “bias risk” assessment tool, bias risk is independently assessed. The independent Newcastle Ottawa scale was used to conduct methodological quality assessment of nonrandomized trials. STATA15.1 and RevMan5.3 software were used to analyze meta outcomes of different intervention measures for the treatment of new crown pneumonia and the control group (conventional antiviral western medicine treatment) clinical efficacy. RESULTS: This study will provide a relatively high-quality synthesis of current evidence of Lianhua Qingwen combined with Conventional antiviral Western Medicine in the treatment of COVID-19 from several aspects including the Clinical effective rate, CT improvement rate, severe conversion rate, antipyretic time, disappearance rate of fever symptoms, disappearance rate of cough symptoms, disappearance rate of asthenia symptoms, and adverse drug events. CONCLUSION: The conclusion of this review will provide evidence to judge whether Lianhua Qingwen combined with Conventional antiviral Western Medicine is an effective and safe intervention for COVID-19. ETHICS AND DISSEMINATION: This systemic review will evaluate the efficacy and safety of Lianhua Qingwen combined with Conventional antiviral Western Medicine in the treatment of COVID-19. Since all the data included are published, the systematic review does not need ethical approval. INPLASY REGISTRATION NUMBER: INPLASY202060067
format Online
Article
Text
id pubmed-7387000
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-73870002020-08-05 Efficacy and safety of Lianhua Qingwen combined with conventional antiviral Western Medicine in the treatment of coronavirus disease (covid-19) in 2019: Protocol for a systematic review and meta-analysis Zhang, Xiaolin Cao, Di Liu, Junnan Zhang, Qi Liu, Mingjun Medicine (Baltimore) 4400 BACKGROUND: The novel coronavirus pneumonia (COVID-19) has spread to >200 countries and regions. There is no effective antiviral drug for COVID-19. Traditional Chinese medicine, such as Lianhua Qingwen, has achieved some curative effect in many countries, but its effect is not clear. We aim to assess the efficacy and safety of Lianhua Qingwen combined with Conventional antiviral Western Medicine in Clinical treatment of COVID-19 or asymptomatic infection. METHODS: The following electronic bibliographic databases will be searched to identify relevant studies: CNKI, CBM, VIP and Wanfang databases, PubMed, EMBASE, MEDLINE, Cochrane central, and clinical trial registration centers, such as China Clinical Trial Registration Center (ChiCTR), Netherlands National Trial Registration Center (NTR) and clinical trials.gov. In addition, Manual retrieval of articles, conference papers, ongoing experiments, internal reports, among others, to supplement electronic retrieval. Select all eligible studies published before May 8, 2020. According to the Cochrane Handbook “bias risk” assessment tool, bias risk is independently assessed. The independent Newcastle Ottawa scale was used to conduct methodological quality assessment of nonrandomized trials. STATA15.1 and RevMan5.3 software were used to analyze meta outcomes of different intervention measures for the treatment of new crown pneumonia and the control group (conventional antiviral western medicine treatment) clinical efficacy. RESULTS: This study will provide a relatively high-quality synthesis of current evidence of Lianhua Qingwen combined with Conventional antiviral Western Medicine in the treatment of COVID-19 from several aspects including the Clinical effective rate, CT improvement rate, severe conversion rate, antipyretic time, disappearance rate of fever symptoms, disappearance rate of cough symptoms, disappearance rate of asthenia symptoms, and adverse drug events. CONCLUSION: The conclusion of this review will provide evidence to judge whether Lianhua Qingwen combined with Conventional antiviral Western Medicine is an effective and safe intervention for COVID-19. ETHICS AND DISSEMINATION: This systemic review will evaluate the efficacy and safety of Lianhua Qingwen combined with Conventional antiviral Western Medicine in the treatment of COVID-19. Since all the data included are published, the systematic review does not need ethical approval. INPLASY REGISTRATION NUMBER: INPLASY202060067 Wolters Kluwer Health 2020-07-24 /pmc/articles/PMC7387000/ /pubmed/32791754 http://dx.doi.org/10.1097/MD.0000000000021404 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 4400
Zhang, Xiaolin
Cao, Di
Liu, Junnan
Zhang, Qi
Liu, Mingjun
Efficacy and safety of Lianhua Qingwen combined with conventional antiviral Western Medicine in the treatment of coronavirus disease (covid-19) in 2019: Protocol for a systematic review and meta-analysis
title Efficacy and safety of Lianhua Qingwen combined with conventional antiviral Western Medicine in the treatment of coronavirus disease (covid-19) in 2019: Protocol for a systematic review and meta-analysis
title_full Efficacy and safety of Lianhua Qingwen combined with conventional antiviral Western Medicine in the treatment of coronavirus disease (covid-19) in 2019: Protocol for a systematic review and meta-analysis
title_fullStr Efficacy and safety of Lianhua Qingwen combined with conventional antiviral Western Medicine in the treatment of coronavirus disease (covid-19) in 2019: Protocol for a systematic review and meta-analysis
title_full_unstemmed Efficacy and safety of Lianhua Qingwen combined with conventional antiviral Western Medicine in the treatment of coronavirus disease (covid-19) in 2019: Protocol for a systematic review and meta-analysis
title_short Efficacy and safety of Lianhua Qingwen combined with conventional antiviral Western Medicine in the treatment of coronavirus disease (covid-19) in 2019: Protocol for a systematic review and meta-analysis
title_sort efficacy and safety of lianhua qingwen combined with conventional antiviral western medicine in the treatment of coronavirus disease (covid-19) in 2019: protocol for a systematic review and meta-analysis
topic 4400
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387000/
https://www.ncbi.nlm.nih.gov/pubmed/32791754
http://dx.doi.org/10.1097/MD.0000000000021404
work_keys_str_mv AT zhangxiaolin efficacyandsafetyoflianhuaqingwencombinedwithconventionalantiviralwesternmedicineinthetreatmentofcoronavirusdiseasecovid19in2019protocolforasystematicreviewandmetaanalysis
AT caodi efficacyandsafetyoflianhuaqingwencombinedwithconventionalantiviralwesternmedicineinthetreatmentofcoronavirusdiseasecovid19in2019protocolforasystematicreviewandmetaanalysis
AT liujunnan efficacyandsafetyoflianhuaqingwencombinedwithconventionalantiviralwesternmedicineinthetreatmentofcoronavirusdiseasecovid19in2019protocolforasystematicreviewandmetaanalysis
AT zhangqi efficacyandsafetyoflianhuaqingwencombinedwithconventionalantiviralwesternmedicineinthetreatmentofcoronavirusdiseasecovid19in2019protocolforasystematicreviewandmetaanalysis
AT liumingjun efficacyandsafetyoflianhuaqingwencombinedwithconventionalantiviralwesternmedicineinthetreatmentofcoronavirusdiseasecovid19in2019protocolforasystematicreviewandmetaanalysis